---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-003808"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T05:20:50.290679+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio discontinues sickle cell gene therapy nula-cel, cuts workforce 50%, explores strategic alternatives

## Summary
- Discontinues development of nula-cel for sickle cell disease; exploring external continuation.
- Reduces workforce by approximately 50%; expects severance costs of ~$4.9M in Q2 2023.
- Chief Business Officer and Chief Scientific Officer to depart in Q2 2023.
- Preliminary unaudited cash, equivalents, and marketable securities of ~$283.5M as of Dec 31, 2022.
- Will continue early-stage non-genotoxic conditioning program; board approved restructuring.

## SEC filing metadata
- accession: 0000950170-23-003808
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/0000950170-23-003808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/grph-20230216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-003808
- JSON: https://secwatch.observer/filing/0000950170-23-003808.json
- Plain text: https://secwatch.observer/filing/0000950170-23-003808.txt

## Key facts
- Restructurings & Charges
  LENZ Therapeutics, Inc. announced a restructuring with charges of approximately $4.9 million (approximately 50%).
  - Type: restructuring
  - Charge: approximately $4.9 million
  - Headcount: approximately 50%
  source text: Under the Plan, the Company is reducing its workforce by approximately 50%. The Company expects to incur estimated severance and related costs of approximately $4.9 million, which will be recorded primarily in the second quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/0000950170-23-003808-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.